Legal & General Group
LYEL icon

Legal & General Group’s Lyell Immunopharma LYEL Stock Holding History

Legal & General Group’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.9K Buy
+917
New +$16.6K ﹤0.01% 3269
2025
Q2 		– Sell
-750
Closed -$8.07K – 3486
2025
Q1 		$8.07K Hold
750
– – ﹤0.01% 3216
2024
Q4 		$9.6K Sell
750
-5,070
-87% -$101K ﹤0.01% 3260
2024
Q3 		$160K Hold
5,820
– – ﹤0.01% 2698
2024
Q2 		$168K Sell
5,820
-356
-6% -$16.9K ﹤0.01% 2686
2024
Q1 		$275K Buy
6,176
+118
+2% +$5.05K ﹤0.01% 2625
2023
Q4 		$235K Hold
6,058
– – ﹤0.01% 2673
2023
Q3 		$178K Buy
6,058
+469
+8% +$22.3K ﹤0.01% 2743
2023
Q2 		$355K Buy
5,589
+4,787
+597% +$265K ﹤0.01% 2570
2023
Q1 		$37.6K Hold
802
– – ﹤0.01% 2922
2022
Q4 		$55.8K Hold
802
– – ﹤0.01% 2937
2022
Q3 		$117K Buy
802
+71
+10% +$9.61K ﹤0.01% 2773
2022
Q2 		$95K Buy
731
+22
+3% +$2.25K ﹤0.01% 2868
2022
Q1 		$72K Buy
709
+599
+545% +$72.6K ﹤0.01% 2934
2021
Q4 		$17K Hold
110
– – ﹤0.01% 3327
2021
Q3 		$33K Buy
110
+86
+358% +$25.8K ﹤0.01% 3093
2021
Q2 		$8K Buy
+24
New +$7.87K ﹤0.01% 3438

Other funds holding LYEL

AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
GP
GSK plc London $602M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $202M AUM 2.79% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $417M AUM 22.81% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $362M AUM 386.37% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

Legal & General Group's LYEL Position: Q2 2026 in Review

Legal & General Group opened a new position in Lyell Immunopharma (LYEL) in Q2 2026: 917 shares worth $12.9K. The stake represents ﹤0.01% of the portfolio and ranks #3269 among its holdings. This is a return to the name: Legal & General Group previously reported a position in LYEL as recently as Q1 2025.

Legal & General Group first reported a position in LYEL in Q2 2021 and has held it in 17 quarters since. The position peaked at $355K in Q2 2023. 87 funds tracked by Wall St. Rank hold LYEL as of Q2 2026.

  • Legal & General Group held 917 shares of Lyell Immunopharma worth $12.9K as of Q2 2026.
  • Lyell Immunopharma was a new Legal & General Group position in Q2 2026.
  • Lyell Immunopharma made up ﹤0.01% of Legal & General Group's portfolio in Q2 2026, its #3269 holding.
  • Legal & General Group first reported a position in Lyell Immunopharma in Q2 2021 and has held it in 17 quarters since.
  • Legal & General Group's Lyell Immunopharma position peaked at $355K in Q2 2023.
  • 87 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q2 2026.

Based on Legal & General Group's 13F filing for Q2 2026, filed 14 Aug 2026.